

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/806382

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 1 Wrapped Aminos
- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 3 Numbering
- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0 A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 6 "bug"
- 7 Skipped Sequences Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 7 (OLD RULES)
- 8 Skipped Sequences Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 8 (NEW RULES)
- 9 Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing.
(NEW RULES) Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10 Invalid <213> Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or
Response scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or
is Artificial Sequence
- 11 Use of <220> Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or
"Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0 Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file,
"bug" resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence
listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

09/806382

SEQUENCE LISTING

110 ASAHI KASEI KABUSHIKI KAISHA

120 Method of controlling secretion of granules
130 ASAHI-3

150 JP10-274574

151 1998-9-29

160

210

211 282

212 DNA

213 human

300

301 Karel Odink et al.

302 Two calcium-binding proteins in infiltrate macrophages
of rheumatoid arthritis

303 Nature

304 330

305 5

306 80-82

307 November 1987

400

atg ttg acc gag ctg gag aaa gcc ttg aac tct atc atc gac gtc tac 48

Met Leu Thr Glu Leu Glu Lys Ala Leu Asn Ser Ile Ile Asp Val Tyr

1

5

10

15

*See item 4 on Ena
summary
Does Not Comply
Corrected Diskette Needed*

*Invalid
Sequence Listing
format*

See next pages (2-3)

09/806,382 2

SEQUENCE LISTING

insert angle brackets around numeric identifiers

(110) ASAHI KASEI KABUSHIKI KAISHA

(128) Method of controlling secretion of granules

(130) ASAHI-3

(150) JP10-274574

(151) 1998-9-29

(160)

mandatory response needed

(210)

211 282

212 DNA

213 human

(300)

301 Karel Odink et al.

302 Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis

303 Nature

304 330

(305)

306 80-82

307 November 1987 NOV-1987

(400)

atg ttg acc gag ctg gag aaa gcc ttg aac tct atc atc gac gtc tac 48
Met Leu Thr Glu Leu Glu Lys Ala Leu Asn Ser Ile Ile Asp Val Tyr

1

5

10

15

misaligned amino acid numbers

cac aag tac tcc ctg ata aag ggg aat ttc cat gcc gtc tac agg gat 96
His Lys Tyr Ser Leu Ile Lys Gly Asn Phe His Ala Val Tyr Arg Asp

20

25

30

gac ctg aag aaa ttg cta gag acc gag tgt cct cag tat atc agg aaa 144
Asp Leu Lys Lys Leu Leu Glu Thr Glu Cys Pro Gln Tyr Ile Arg Lys

35

40

45

aag ggt gca gac gtc tgg ttc aaa gag ttg gat atc aac act gat ggt 192
Lys Gly Ala Asp Val Trp Phe Lys Glu Leu Asp Phe Asn Thr Asp Gly

50

55

60

gca gtt aac ttc cag gag ttc ctc att ctg gtg ata aag atg ggc gtg 240

Ala Val Asn Phe Gln Glu Phe Leu Ile Leu Val Ile Lys Met Gly Val

65

70

75

80

delete blank line

gca gcc cac aaa aaa agc cat gaa gaa agc cac aaa gag tag 282
Ala Ala His Lys Lys Ser His Glu Glu Ser His Lys Glu

85

90

(210)

211 345

212 DNA

09/806,382 3

213 human

300

301 Karel Odink et al.

302 Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis

303 Nature

304 330

305 5

306 80-82

307 November 1987

NOV-1987

400

2

atg act tgc aaa atg tcg cag ctg gaa cgc aac ata gag acc atc atc 48
Met Thr Cys Lys Met Ser Gln Leu Glu Arg Asn Ile Glu Thr Ile Ile
1 5 10 15

aac acc ttc cac caa tac tct gtg aag ctg ggg cac cca gac acc ctg 96
Asn Thr Phe His Gln Tyr Ser Val Lys Leu Gly His Pro Asp Thr Leu
20 25 30

aac cag ggg gaa ttc aaa gag ctg gtg cga aaa gat ctg caa aat ttt 144
Asn Gln Gly Glu Phe Lys Glu Leu Val Arg Lys Asp Leu Gln Asn Phe
35 40 45

ctc aag aag gag aat aag aat gaa aag gtc ata gaa cac atc atg gag 192
Leu Lys Lys Glu Asn Lys Asn Glu Lys Val Ile Glu His Ile Met Glu
50 55 60

gac ctg gac aca aat gca gac aag cag ctg agc ttc gag gag ttc atc 240
Asp Leu Asp Thr Asn Ala Asp Lys Gln Leu Ser Phe Glu Glu Phe Ile
65 70 75 80

atg ctg atg gcg agg cta acc tgg gcc tcc cac gag aag atg cac gag 288
Met Leu Met Ala Arg Leu Thr Trp Ala Ser His Glu Lys Met His Glu
85 90 95

ggc gac gag ggc cct ggc cac cac cat aag cca ggc ctc ggg gag ggc 336
Gly Asp Glu Gly Pro Gly His His His Lys Pro Gly Leu Gly Glu Gly
100 105 110

acc ccc taa 345
Thr Pro

misaligned
nos.

4 Delete at end of file

FYI →

Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

all sample Sequence Listings (attached) for valid format

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001
<141> 1998-12-31

<150> US 08/999,999
<151> 1997-10-15

<160> 4

<170> PatentIn version 2.0

<210> 1
<211> 389
<212> DNA
<213> Paramecium sp.

<220>
<221> CDS
<222> (279)...(389)

<300>
<301> Doe, Richard
<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.
<303> Journal of Genes
<304> 1
<305> 4
<306> 1-7
<307> 1988-06-31
<308> 123456
<309> 1988-06-31

<400> 1
agctgtagtc attcctgtgt cctcttctct ctgggcttct caccctgcta atcagatctc 60
agggagagtg tcttgaccct cctctgcctt tgcagcttca caggcaggca ggcaggcagc 120
tgatgtggca attgctggca gtgccacagg cttttcagcc aggccttaggg tgggttccgc 180
cgcggcgcgg cgccccctct cgcgctcctc tcgcgcctct ctctcgctct cctctcgctc 240

Appendix 3, page 2

ggacctgatt	aggtgagcag	gaggaggggg	cagtttagc	atg Met 1	ggt Val	tca Ser	atg Met	ttc Phe 5	agc Ser	296						
ttg Leu	tct Ser	ttc Phe	aaa Lys 10	tgg Trp	cct Pro	gga Gly	ttt Phe	tgt Cys 15	ttg Leu	ttt Phe	ggt Val	tgt Cys	ttg Leu 20	ttc Phe	caa Gln	344
tgt Cys	ccc Pro	aaa Lys 25	gtc Val	ctc Leu	ccc Pro	tgt Cys	cac His 30	tca Ser	tca Ser	ctg Leu	cag Gln	ccg Pro 35	aat Asn	ctt Leu	389	
<210>	2															
<211>	37															
<212>	PRT															
<213>	Paramecium sp.															
<400>	2															
Met 1	Val	Ser	Met	Phe 5	Ser	Leu	Ser	Phe	Lys 10	Trp	Pro	Gly	Phe	Cys 15	Leu	
Phe	Val	Cys	Leu 20	Phe	Gln	Cys	Pro	Lys 25	Val	Leu	Pro	Cys	His 30	Ser	Ser	
Leu	Gln	Pro 35	Asn	Leu												
<210>	3															
<211>	11															
<212>	PRT															
<213>	Artificial Sequence															
<220>																
<223>	Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.															
<400>	3															
Met 1	Val	Asn	Leu	Glu 5	Pro	Met	His	Thr	Glu 10	Ile						
<210>	4															
<400>	4															
000																

[Annex VIII follows]

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOs	Count includes total number of SEQ ID NOs	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		in feature	base was used in a sequence
<223>	Other Information	Other relevant information; four lines maximum	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<300>	Publication Information	Leave blank after <300>	0
<301>	Authors	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials	0
<302>	Title		0
<303>	Journal		0
<304>	Volume		0
<305>	Issue		0
<306>	Pages		0
<307>	Date	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy	0
<308>	Database Accession Number	Accession number assigned by database including database name	0
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy	0
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999	0

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	O
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	O
<313>	Relevant Residues	FROM (position) TO (position)	O
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	M

5. Section 1.824 is revised to read as follows:

1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.821(c) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;